Latest Articles

Publication Date
Abemaciclib Plus Letrozole Displays Durable Activity in Advanced/Recurrent Endometrioid Endometrial Carcinoma - OncLive

Abemaciclib Plus Letrozole Displays Durable Activity in Advanced/Recurrent Endometrioid Endometrial Carcinoma OncLive

Published: April 11, 2026, 4:04 p.m.
Neoadjuvant Chemotherapy Followed by Radical Cytoreductive Surgery in Serous Endometrial Carcinoma With Inguinal Lymph Node Metastasis: A Case Report - Cureus

Neoadjuvant Chemotherapy Followed by Radical Cytoreductive Surgery in Serous Endometrial Carcinoma With Inguinal Lymph Node Metastasis: A Case Report Cureus

Published: April 9, 2026, 9:38 a.m.
CAR-NKT cell therapy offers scalable, off-the-shelf immunotherapy for endometrial carcinoma - Oncology Central

CAR-NKT cell therapy offers scalable, off-the-shelf immunotherapy for endometrial carcinoma Oncology Central

Published: March 23, 2026, 9:45 a.m.
CAR-NKT cell therapy: a scalable immunotherapy option for endometrial carcinoma - Oncology Central

CAR-NKT cell therapy: a scalable immunotherapy option for endometrial carcinoma Oncology Central

Published: March 23, 2026, 9:45 a.m.
Pernille Bjerre Trent: Publishes New Article on Avoiding Radiotherapy in Endometrial Carcinoma - Oncodaily

Pernille Bjerre Trent: Publishes New Article on Avoiding Radiotherapy in Endometrial Carcinoma Oncodaily

Published: March 7, 2026, 6:34 p.m.
Deep learning-based automated detection of endometrioid endometrial carcinoma in histopathology - Frontiers

Deep learning-based automated detection of endometrioid endometrial carcinoma in histopathology Frontiers

Published: Dec. 8, 2025, 10:41 a.m.
A rare curious case of ureteric dissection in a patient with vaginal vault recurrence of endometrial carcinoma - SpringerOpen

A rare curious case of ureteric dissection in a patient with vaginal vault recurrence of endometrial carcinoma SpringerOpen

Published: Nov. 25, 2025, 8:52 a.m.
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - 뉴스와이어

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma 뉴스와이어

Published: Nov. 13, 2025, 5:50 a.m.
FDA Clears New CDx for Pembrolizumab/Lenvatinib in Endometrial Carcinoma - Targeted Oncology

FDA Clears New CDx for Pembrolizumab/Lenvatinib in Endometrial Carcinoma Targeted Oncology

Published: Nov. 12, 2025, 7:08 p.m.
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - BioSpace

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma BioSpace

Published: Nov. 12, 2025, 4:01 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!